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ABSTRACT
HIGH THROUGHPUT SCREENING FOR THE ENHANCEMENT OF ADENOASSOCIATED VIRUS TYPE 2 TRANSDUCTION
Alexis Jessica Wallen
Dr. Scott L. Diamond
Adeno-associated virus (AAV) is a promising vector for human gene therapy. Although
more effective than non-viral vectors, AAV still requires improvement in efficacy in
order to become a successful gene therapy vector. With this in mind, we have sought to
identify and examine identified enhancers of adeno-associated virus type 2 (AAV2)
transduction.

Using a high throughput screening system with recombinant AAV2

carrying the luciferase reporter gene (AAV2-Luc), we found siRNA sequences and
chemical compounds which increase AAV2 reporter gene expression. We specifically
identified a hexamer seed region 5’-UGUUUC-3’ which facilitated AAV2 transduction.
Chemical compound enhancers included ellagic acid, 1,10-phenanthroline, EGFR
tyrosine kinase inhibitors, nucleoside analogs, and DNA alkylating agents. Although
several of these compounds, such as EGFR tyrosine kinase inhibitors and DNA
alkylating agents, were known enhancers of AAV transduction, compounds such as
ellagic acid and 1,10-phenanthroline were newly identified as facilitating AAV2
transduction. After identifying these enhancers, we have further sought to understand a
mechanistic basis for them through studies which individually quantified enhancement at
v

stages including the virus-receptor interaction, the viral DNA introduction into the cell,
reporter gene RNA transcription, and the production of protein from the transgene. The
identification of siRNAs and chemical compounds which enhance transduction can lead
to a better understanding of AAV2 biology and may provide a foundation for the
engineering of novel AAV formulations, delivery systems, or vectors.
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Chapter 1

1. Introduction
Modern medicine has led to major advances in the prevention and treatment of human
diseases. Drugs and biotechnology products are available to treat a variety of ailments.
Antibiotics serve as an effective cure for bacterial infections, many pills can treat disease
by blocking or promoting a particular biological pathway, vaccines can prevent infection,
and monoclonal antibodies can treat cancer as well as other diseases. However, many
illnesses still cannot be adequately addressed with existing medications. Gene therapy,
the use of nucleic acids to prevent or treat a disease, is a novel approach that holds
promise for treating many of these conditions.

Either ribonucleic acid (RNA) or

deoxyribonucleic acid (DNA) are introduced using either a non-viral or viral delivery
vehicle, called a vector. Although non-viral methods have many advantages, including a
low risk of pathogenicity, non-viral methods have thus far failed to show adequate
transgene expression for therapeutic benefit. Viral gene therapy methods hold great
potential, however, further research is required to develop a safe and effective gene
therapy vector. In this work, we will focus on high throughput screening for enhancers of
adeno-associated virus type 2 (AAV2), a promising vector for viral-mediated gene
delivery.
1

1.1. Non-viral Gene Therapy
Traditional non-viral methods of gene therapy include injection of “naked” plasmid DNA
or of a formulation which packages the DNA. In the first case, plasmid DNA is injected
directly. In the second case, plasmid DNA is formulated with either a lipid or polymer.
In a cationic lipid system, the positively charged lipid associates with the negatively
charged DNA. This both condenses the DNA and shields the negative charge from the
cell’s lipid bilayer membrane, facilitating transport of the DNA into the cell. A similar
system can be formulated using polymers which mimic lipids, but which allow special
engineering and targeting of the system1, 2. Variations on these systems include the use
of electroporation, gold nanoparticles, or ultrasound to enhance delivery3.
Although these systems are considered safer than viral methods, there is potential for the
non-viral carrier to elicit an immune response to both the carrier as well as to the
transgene. Care must be taken in the design of such as system in order to minimize an
immune system response.
While non-viral gene delivery does have several characteristics making it desirable for
gene therapy applications, it has thus far been limited by low transgene expression. The
main application of plasmid DNA for gene therapy has been the development of
vaccines, which require only a small amount of antigen to be expressed in order for the
immune system to respond. However, even DNA vaccines have shown limited success4, 5.

2

1.2. Viral Gene Therapy
Viral gene therapy has the advantage of being more efficient than non-viral gene therapy.
Viruses have evolved over time to be highly capable of transducing human cells, and the
wide variety of virus strains allows researchers a large toolbox of characteristics from
which to choose. Some viruses are specific to certain types of tissue or to dividing or
non-dividing cell types. Viruses can be selected that do or do not integrate into the
genome.
While it is helpful to have so many different viruses from which to choose, most viral
methods of gene delivery do present a safety concern, especially given the clinical history
of treatments with retroviruses and adenovirus. In the case of retrovirus, the gene therapy
succeeded in curing X-linked severe combined immunodeficiency (X-linked SCID), but
several of the patients developed leukemia6-9. In the case of adenovirus, a 1999 clinical
trial for the liver-directed gene therapy treatment of ornithine transcarbamylase
deficiency led to the immune-response linked death of a patient10, 11. Although these
trials showed promise for efficacy of human gene therapy, it was clear that the
development of a safer vector was needed. Adeno-associated virus (AAV) is seen as a
promising viral vector for gene delivery with a strong safety profile.

1.3. Adeno-associated Virus as a Gene Therapy Vector
AAV, although widespread in the population, has not been known to cause any human
disease. This small virus, with a diameter of 20 nm packaging 4.7 kb of single-stranded
3

DNA, was originally discovered as a contaminant in an adenovirus preparation and is
incapable of replicating in the absence of a helper virus12. The engineered virus
additionally has all replication genes removed, so replication does not proceed even if a
helper virus is present. The wild-type virus integrates into the human genome at a
specific location on chromosome 19 which has not been implicated in oncogenesis

13, 14

.

The engineered virus does not integrate into the genome due to the missing Rep gene
which facilitates integration

15, 16

. In general, the low immune response and lack of

associated human disease make it a strong candidate for viral gene therapy. The virus
additionally exists in nature in a variety of serotypes, which show differences in tropism
for various target organs within the human body.
Adeno-associated virus does, however, have some disadvantages as a vector. Because
the engineered virus lacks the ability to insert into the chromosome, gene expression will
be lost over time in dividing cell types. Additionally, thus far success in clinical trials has
been elusive due to limited transgene expression. In laboratory experiments, previous
researchers have found a range of anywhere from 1 in 100 to 1 in 10 6 viral particles will
succeed in transducing cells, depending upon the cell line and conditions used

17-19

.

However, strong advances are being made in increasing transduction efficiency through
directed evolution of virus and targeted virus mutations.

1.4. Adeno-associated Virus type 2 biology
In this work, we have chosen to focus on adeno-associated virus type 2 (AAV2), as it is
the most well-characterized serotype. The biological pathway for AAV viral entry and
4

gene expression contains numerous steps involving host proteins that control the level of
transgene delivery and expression. First, AAV must bind to heparin sulfate proteoglycan
cell surface receptors

20, 21

.

Following binding, AAV must be endocytosed in the

presence of αVβ5 integrin and with activation of Rac-1 21. Following endosome escape,
the viral genome must gain entry to the nucleus, where viral DNA synthesis and
transcription of the viral genome take place.

Figure 1.1: Adeno-associated viral transduction. Viral particles attach to cell surface
receptors, are endocytosed via a clathrin-coated pit, escape from the endosome, are
transported to the perinuclear space, cross the nuclear membrane, are uncoated, and the
second strand of DNA is synthesized. Once double-stranded DNA is in place, normal
cellular machinery is used to transcribe DNA to RNA, which is then transported out of
the nucleus, where RNA is translated to protein.
In this work, we seek to add to the adeno-associated virus literature in an attempt to
enhance adeno-associated virus transduction efficiency. Although this virus has been
extensively studied, there are still many unknowns in the viral transduction pathway.
Here, we use two high throughput screens to better understand the virus, with the dual
5

goals of providing insight into the biology of the virus and providing new information to
benefit future efforts to design better formulations and/or engineer next generation AAV
serotypes.

1.5. Pseudotyped AAV
AAV exists in nature in a variety of serotypes which have slight differences.

For

example, whereas type 2 binds to heparan sulfate proteoglycan, type 1 binds to sialic acid
on the cell surface and type 9 binds to galactose on the cell surface

22, 23

. Coreceptors

additionally facilitate the binding to these primary receptors. A pseudotyped vector
contains the capsid from one serotype and the genome from a different serotype, allowing
independent manipulation of the viral capsids and genome 24-26.

1.6. RNA Interference
RNA interference is a naturally occurring process in which antisense RNA is used to
generate a host cell response which leads to the degradation of the complementary
RNA27. siRNA, or short interfering RNA, is a short double-stranded RNA of 21-23
nucleotides which effectively uses this cellular machinery to generate a strong knockdown of RNA 28. This knock-down of RNA leads to a decrease in corresponding protein,
allowing loss-of-function experiments.
Despite optimization of siRNA sequence selection, both sequence-dependent and
sequence-independent off-target effects may occur, causing unintended effects

29-36

. For
6

example, an individual siRNA targeting a particular gene can show a different mRNA
expression profile from another siRNA that successfully targets the same gene

29

. An

additional type of sequence-dependent off-target effect arises from the hexamer seed
region, located at positions 2-7 of the siRNA sequence. This region can bind to the
3’UTR of various mRNA species and can lead to a complex pattern of mRNA cleavage
and translational silencing

31, 33

, thereby functioning in a similar manner as microRNA

(miRNA).
In the first of two high throughput screens described in this work, we utilize this
mechanism to identify siRNA enhancers of viral transduction.

Figure 1.2: Mechanism of siRNA and miRNA pathway. A) In the siRNA pathway,
double-stranded siRNA is introduced into the cell, where it is recognized by and loaded
into the RNA-induced silencing complex (RISC). When complementary mRNA is
found, the RNase is activated and cleaves the mRNA strand. B) in the miRNA pathway,
similar events occur, however the miRNA can be either perfectly complementary to the
mRNA or complementary to only the hexamer seed region. The result is either mRNA
degradation or translational repression.
7

1.7. Chemical Modifiers of Viral Transduction
As described in section 1.4, the interaction between viruses and host cells is complex.
Chemical modifiers have the potential to interact with the virus or its products at each
step of the viral transduction pathway and to activate or inhibit these stages. In a second
high throughput screen, we used small molecule chemical compounds known to be
pharmacologically active in order to perturb this system and learn more about the cellvirus interaction and enhancements of this interaction.

1.8. Objectives
The overarching goal of this work was identification of enhancers of AAV2 transduction,
with the desired outcome of learning more about the AAV2 pathway and providing
information that can lead to the engineering or formulation of a more effective AAV2
vector. In order to do so, we have conducted two high throughput screens. In the first,
we examined siRNA and were able to identify a consensus hexamer seed region. In the
second, we identified several chemical compound enhancers of AAV2, some previously
known to enhance AAV2 and some which were newly identified.

8

Chapter 2

2. siRNA High Throughput Screen
The majority of this work has been published in Molecular Therapy.37
Adeno-associated virus (AAV) is a promising vector for gene delivery. AAV vectors
have several advantages including: low pathogenicity, low immune response, long term
episomal expression in nondividing cell types, and specific organ targeting based on the
serotype used 38-41. However, insufficient transgene expression has limited the success of
a number of human clinical trials that used AAV vectors

42-45

. Although AAV vectors

result in higher transduction than nonviral methods, a major goal is to increase the
efficiency of gene transfer. This cannot be simply overcome by continually increasing
vector dosages, as higher doses are more likely to elicit an immune response and would
present additional challenges to manufacturing capacity, cost of treatment, and/or
treatment administration.
Although the early steps of binding and endocytosis are well studied, many virus-host
interactions remain unknown which may enhance or reduce viral transgene expression.
The ability of knocking down individual targets makes siRNA extremely useful for high
throughput screening.

A number of published studies have used this technique to

examine virus/host cell interactions46-52, usually in the context of reducing viral infection
(as opposed to enhancing transgene expression).
9

To help identify intracellular barriers to AAV transgene expression, we conducted a high
throughput screen using short interfering RNA (siRNA) to knock-down mRNA
corresponding to 5,520 Applied Biosystems “druggable genome” targets. In the present
study, off-target effects caused by a common seed region sequence were observed in 4 of
the top 5 screening hits. Also, mRNA profiling was used to investigate additional offtarget effects where a complex phenotype emerged involving downregulation of genes of
the interferon pathway.

2.1. Materials and Methods
2.1.1. Cell culture
Human Aortic Endothelial Cells (HAEC; Lonza, Walkersville, MD) were cultured in
supplemented Clonetics EGM-2 (Lonza, Walkersville, MD) at 37ºC and 5% CO2. Prior
to siRNA treatment, cells were rinsed with Dulbecco’s phosphate-buffered saline and
incubated with 0.05% Trypsin-EDTA (Invitrogen, Santa Clara, CA), then seeded onto 96
or 384 well flat bottom plates (BD Bioscience, Franklin Lakes, NJ).

Human bronchial

epithelial cells (Lonza, Walkersville, MD) were grown in cell culture flasks containing
supplemented bronchial epithelial growth media (BEGM) for 4-5 days at 37ºC and 5%
CO2. Human bronchial epithelial cells were then seeded at a density of 10 5 per well onto
96 well flat bottom plates (BD Bioscience, Franklin Lakes, NJ) and cultured in an equal
mixture of bronchial epithelial basal media and Dulbecco’s modified Eagle’s medium

10

(Invitrogen, Santa Clara, CA). Cells became confluent within 4 days and were allowed to
grow for 2 weeks prior to forward transfection.

2.1.2. Druggable genome library
The Druggable Genome Library (Applied Biosystems, Foster City, CA) was used for
screening. This library consists of 5,520 gene targets and 3 siRNAs per gene. The
library was provided in 384 well plates, each well containing 0.25 nmol of lyophilized
siRNA. The two columns on the right of the plate were left empty for controls. Sterile
nuclease-free water (Applied Biosystems, Foster City, CA) was added to each well in
order to resuspend the siRNA at a concentration of 3125 nM. Additional nuclease-free
water was used to dilute the siRNA to a working concentration of 330 nM. For the
primary screen, the three siRNAs targeting the same gene were pooled together in equal
quantities to create a pooled master. The pooled master was then used to create assay
plates containing 2 µL of siRNA, with each individual siRNA at a concentration of 110
nM, for a total pooled siRNA concentration of 330 nM. For the confirmatory screen, the
desired individual siRNAs were aliquoted from the diluted master, and used to create
assay plates containing 2 µL of siRNA, with each individual siRNA at a concentration of
330 nM. Seven columns on the right and left sides of each plate contained controls.
Following the confirmatory screen, work was performed at larger scale (96 wells or less
per plate), and in those cases the siRNA were ordered individually and resuspended using
sterile nuclease-free water at a concentration of 3125 nM.

11

2.1.3. Mutated siRNAs
For examination of off-target effects resulting from the seed region of the siRNA
sequences, three mutated siRNA sequences were designed in which individual point
mutations were introduced into positions 1, 4, and 14, respectively, of the siRNA strand
corresponding to Applied Biosystems siRNA 145736 (CLIC2 sequence C). In each case,
the siRNA sense strand was complementary to its mutated antisense strand. The mutated
siRNAs were chemically identical to the original Applied Biosystems Silencer siRNAs,
with the exception of the point mutations, and sequences are given in Table 2.1.
Gene
Name

siRNA Letter
ID#
Code

B
SLC5A2 41847
A
ABCA8 117435
145736
C
CLIC2
B
GPR124 34695
668
A
LCK
CLIC2(C)-A1U mutant
CLIC2(C)-U4A mutant
CLIC2(C)-G14C mutant

Antisense Sequence

5’-ACAGUGCCUCUGUUGGUUCtg-3’
5’-UUGUUUCAUAACAAUGAGCtg-3’
5’-AUGUUUCUAAGGAGCAGGGtg-3’
5’-AUGUUUAGUCGGAGAAGCCtg-3’
5’-AUGUUUCACCACCUCUCCCtg-3’
5’-UUGUUUCUAAGGAGCAGGGtg-3’
5’-AUGAUUCUAAGGAGCAGGGtg-3’
5’-AUGUUUCUAAGGACCAGGGtg-3’

Primary
Screen Fold
Increase
(pooled)
13.9
17.7
16.9
7.0
22.1

Secondary
Screen Fold
Increase
(single siRNA)
6.0
4.6
4.3
3.4
3.4

Table 2.1. siRNA sequences providing the top hits in secondary screening of individual
siRNAs, and point-mutated siRNA sequences based on CLIC2 sequence C. The bases

shared in the seed region between four of the five sequences are italicized. The point
mutations made to CLIC2 sequence C are in bold font and underlined.

2.1.4. Reverse transfection protocol
The protocol used for HAEC transfection was adapted from the method described by
Barker and Diamond 53. HAEC were cultured in Clonetics EGM-2 (Lonza, Walkersville,
MD).

siRNA (Applied Biosystems, Foster City, CA) was added to a well plate. The
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well plate was either frozen overnight or held at room temperature for less than two
hours.

If the plate was frozen, it was thawed and allowed to equilibrate to room

temperature prior to use. siPort NeoFX™ (Applied Biosystems, Foster City, CA) diluted
in Opti-Mem™ (Lonza, Walkersville, MD) was added to the siRNA plate and allowed to
incubate at room temperature for 10 minutes. HAEC grown in a cell culture flask were
then added to the plate at a seeding density of 4.5 x 104 cells per cm2. The siRNA were
allowed to transfect the cells for 24 hours.

2.1.5. Forward transfection protocol
siRNA (Applied Biosystems, Foster City, CA) was thawed at room temperature and then
added to siPort NeoFX™ (Applied Biosystems, Foster City, CA) diluted in Opti-Mem™
(Lonza, Walkersville, MD). The mixture was allowed to incubate at room temperature
for 10 minutes prior to addition to 96 well plates. The siRNA were allowed to transfect
the cells for 24 hours.

2.1.6. Interferon protocol
Frozen recombinant human αA-Interferon and β-Interferon (Calbiochem, San Diego, CA)
were thawed on ice and diluted in Dulbecco’s Phosphate Buffered Saline (Invitrogen,
Santa Clara, CA) and serially diluted prior to addition to a 96 well plate. Virus addition
followed within 20 minutes of addition of interferon to the well plate.
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2.1.7. Luciferase transduction protocol
Adeno-associated virus, type 2, containing a CMV promoter and firefly luciferase
sequence (AAV2-Luc) was added to the well plate. The virus was then allowed to
transduce the cells for 24 hours. On the third day, cells were assayed for gene expression
using the Bright-Glo assay kit (Promega, Madison, WI) following the vendor’s protocol.
A scrambled siRNA sequence was used as a negative control (Silencer Negative Control
1; Applied Biosystems, Foster City, CA).

2.1.8. Fluorescence transduction protocol
After 24 hours of exposure to siRNA, adeno-associated virus, type 2, containing a CMV
promoter and enhanced green fluorescent protein sequence (AAV2-EGFP) was added to
the plate. The virus was then allowed to transduce the cells for a minimum of 48 hours
prior to imaging and flow cytometry analysis.

2.1.9. Flow Cytometry
An Accuri C6 Flow Cytometer (Accuri Cytometers, Ann Arbor, MI) was used for
quantitative analysis of individual cell fluorescence.

Cells were harvested into

Dulbecco’s Phosphate Buffered Saline (Invitrogen, Santa Clara, CA) and then held on ice
until measurement. 20,000 counts per sample were recorded.
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2.1.10. Cell viability assay
Cells were assayed for viability using the Cell Titer Glo assay kit (Promega, Madison,
WI) following the vendor’s protocol.

2.1.11. Quantitative real-time PCR
Cells were treated with siRNA and were then harvested a day later for total RNA content
using the Absolutely RNA microprep kit (Stratagene, La Jolla, CA). Superscript III
reverse trasnscriptase and oligo(dT) (Invitrogen, Carlsbad, CA) was used to reverse
transcribe the RNA. The resulting cDNA was then purified using the Qiagen PCR
purification kit (Qiagen, Valencia, CA).
CACTACAAGCTAGACGGT

and

The CLIC2 forward primer used was
the

reverse

primer

used

was

CCAGGAACGGAGGATT. The MX1 forward and reverse primers, respectively, were
CGCAGGGACCGCCTTGGACC and GGGTGGGATGCAGCAGCTGGA. The IFI44L
forward

primer

and

reverse

primers

used

were,

respectively,

GGTGGGTCCAGTTGGGTCTGGA and GCACAGTCCTGCTCCTTCTGCC.
IFIT5

forward

and

reverse

primers

used

were,

respectively,

AGGCTGTTACCCTGAACCCAGAT and GGTCTGTTGTGTGTGGCCTTCT.
GAPDH transcript was used to normalize between samples.

The

The

The GAPDH forward

primer and reverse primers were, respectively, TGCACCACCAACTGCTTAGC and the
GGCATGGACTGTGGTCATGAG. A Roche LightCycler (Indianapolis, IN) was used
to generate a standard curve and optimize PCR conditions for each primer.

The
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LightCycler FastStart DNA MasterPLUS SYBR Green I kit (Roche, Indianapolis, IN)
and Light Cycler melting curve analysis was used to perform quantitative real-time PCR.

2.1.12. Transcription Profiling
Cells were grown in 24 well plates at a seeding density of 45,000 cells/cm 2. Cells were
harvested using 0.05% Trypsin-EDTA (Invitrogen, Carlsbad, CA) 24 hours after siRNA
transfection. Total RNA was purified from cell lysate using the Absolutely RNA kit
(Agilent, Santa Clara, CA). For each sample, 0.2-0.3 ug of purified RNA was amplified,
fragmented, and then hybridized to the Human Gene 1.0ST microarray (Affymetrix,
Santa Clara, CA)according to the Affymetrix GeneChip Expression Analysis Technical
Manual protocol. Following hybridization, washing, and staining, the microarray was
imaged using a confocal scanner with fluorescence excitation at 570 nm. Two sequential
scans were conducted and a mean fluorescence signal was calculated. The resulting
signals were analyzed using the Affymetrix Microarray Suite 5.0 and default values
provided by Affymetrix.

Fold change, p-value, and Significance Analysis of

Microarray54 (SAM) q-value were calculated. Transcripts whose SAM q-value were less
than 25 and having a fold-change difference greater than 1.25 (indicating up-regulation)
or less than -1.25 (indicating down-regulation) were identified.
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2.1.13. Identification of hexamer seed region in 3’ untranslated
region
The UTRdb55,

56

contains the untranslated sequences of eukaryotic mRNAs. The 3’

untranslated regions of each of the top 50 genes identified as a possible hit in siRNA
primary screening as well as the 3’ untranslated regions of genes identified in
transcription profiling were searched for the presence of the hexamer seed region 5’GAAACA-3’.

2.2. Results
2.2.1. Primary and secondary screening
An siRNA library targeting 5,520 gene sequences was screened as pools (3 siRNA
pooled per targeted gene) to examine the effect of each targeted gene on AAV2
transduction of cultured human aortic endothelial cells (HAEC). Three siRNAs at a
concentration of 10 nM per targeted gene were pooled (30 nM total) and reverse
transfected into human aortic endothelial cells (HAEC) in three replicate wells. At 1 day
post-siRNA delivery, the HAEC were transduced with AAV2 coding for the firefly
luciferase gene (AAV2-Luc) at 8.60 x 106 genome copies per well and the luciferase was
then assayed 24 hr post-transduction (Figure 2.1a). The Robust Z-factor 53, 57 provides a
metric of the median absolute deviation by which an individual knockdown condition
(averaged over 3 replicates) differs from the population median (median luminescence
17

signal of 3.9 x 103 RLU). A total of 50 hits (~1 % hit rate) were scored as those siRNA
pools with Robust Z-factor > 4.75, corresponding to replicate wells having >8.4-fold
enhancement of luciferase expression.
The top 50 hits from the pooled primary screening were confirmed in a secondary screen
by testing individually each of the three siRNAs (not shown). In this confirmation test,
each individual siRNA was added such that the siRNA concentration prior to virus
addition was 30 nM (See Appendix Table A1 for siRNA sequences). A total of 10
targeted genes were confirmed that had at least one siRNA sequence providing
significant improvement in transduction efficiency (Figure 2.1b). Three of the top ten
gene hits (SLC13A4, SLC5A2, SLC5A3) came from solute carrier families, with
sequence B against SLC5A2 resulting in greater than 6-fold enhancement of luciferase
transgene expression.

Sequence C against CLIC2 resulted in greater than 4-fold

enhancement of transgene expression.
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Figure 2.1. Primary and secondary screening for siRNA enhancers of AAV
transduction. (a) Robust Z-factor for 5,520 siRNA pools (average of three replicates)
examined in primary screen for enhancement of AAV transduction as detected by
enhancement of the luciferase transgene. A cut-off of Robust Z-factor > 4.75 defined 50
hits (red). Data from untreated wells (average of eight replicates) is shown on the right.
Z-factor = 0 (median) and Z = 3.0 are marked as a reference. (b) A total of 10 of the top
50 pooled screening hits were confirmed as enhancers of AAV transduction when each
siRNA (sequences A, B, C) of each pool was tested individually. At least one of the
three sequences tested in each pool resulted in a significant enhancement of luciferase
expression.
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Cell viability following knockdown with SLC5A2 sequence B and CLIC2 sequence C
was unchanged (Figure 2.2), indicating that enhancements in transgene expression were
not likely due to toxicity of a particular siRNA sequence.

Figure 2.2. Viability of HAEC following siRNA knockdown with indicated
sequences. HAEC were reverse transfected with indicated siRNA sequences and were
assayed for viability 24 hours later.

2.2.2. Off-target effect of siRNA sequences against CLIC2
Since only sequence C against CLIC2 enhanced transgene expression, we used qRT-PCR
to verify the extent of CLIC2 mRNA knockdown. As shown in Figure 2.3, the amount
of CLIC2 mRNA knockdown was similar for each sequence at siRNA concentrations of
30 nM or 100 nM. We conclude that the mechanisms by which sequence C caused a
20

substantial, dose-dependent increase in AAV2 transduction was not due to the reduction
in CLIC2 mRNA.

Figure 2.3. Demonstration of off-target mechanism of action of CLIC2 siRNA. (a)
qRT-PCR measurement of CLIC2 mRNA knockdown in HAEC at 24 hr following
transfection with 3 different siRNA sequences at concentrations of 30 nM and 100 nM,
normalized against GAPDH mRNA signal. (b) Luciferase luminescence relative to
scrambled siRNA negative control for CLIC2 siRNA sequences A, B, and C used at four
concentrations of 10, 30, 50, and 100 nM. AAV transgene expression was uncorrelated
with CLIC2 mRNA knockdown.

2.2.3. Seed region off-target effects
Analysis of the top siRNA sequence hits from single siRNA confirmation screening
revealed that 3 of the top 5 shared an identical nucleotide sequence at positions 2-7 of the
antisense strand and that a fourth siRNA shared positions 2-6 with those sequences
(Table 2.1).

To investigate if the observed off-target effect stemmed from this

U2GUUUC7 seed region of the antisense strand, three siRNAs consisting of the CLIC2
sequence C containing point mutations were examined (Table 2.1). These siRNAs were
then transfected into HAEC at a range of concentrations from 10 to 100 nM and AAV221

Luc was added 24 hr later (Figure 2.4). Where the point mutation was introduced into
position 1or position 14 of the sequence, increases in transduction were comparable to the
original CLIC2 sequence C. However, when the U4A point mutation was introduced into
the middle of the hexamer seed region, the siRNA sequence performance was similar to
the negative control and did not display the increases in transduction efficiency observed
with the other sequences. Comparison of knockdowns with the CLIC2 sequence C and
the mutated CLIC2 sequence C in which the nucleotide at position four (U4A) indicates a
microRNA-like mechanism for the off-target siRNA mediated enhancement of luciferase
expression.

Figure 2.4.
Hexamer region of CLIC(C) antisense strand mediates enhanced
AAV2 transgene expression. Effect of CLIC2 siRNA sequence C and CLIC2(C) siRNA
mutants on AAV2 transduction of HAEC, normalized to scrambled siRNA negative
control.
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2.2.4. Identification of hexamer seed region in 3’ untranslated
region
The 3’ untranslated region of genes identified in primary screening were searched for
complementarity to the hexamer seed region 5’-UGUUUC-3’ (the sequence 5’GAAACA-3’ was searched for in the 3’ untranslated region). The results are presented
in Appendix Table A1. No trends were found with regards to the presence or absence of
this sequence within the 3’ untranslated region.

2.2.5. Transcription profiling following siRNA transfection
implicate interferon pathways
Additional off-target effects of siRNA can arise through global phenotypic changes in the
mRNA profile due to the siRNA. Differences in the mRNA expression profile between
CLIC2(C) and CLIC2(C)-U4A mutant sequences due to off-target effects specific to the
hexamer seed region were tested by mRNA profiling. In comparing the HAEC response
to CLIC2 sequence C versus U4A mutant siRNA sequence (no AAV2 added), a total of
28 transcripts were enhanced, while 40 transcripts were decreased (Appendix Table A2)
Several transcripts related to the interferon pathway were downregulated: interferoninduced protein 44-like (IFI44L), interferon-inducible myoxovirus resistance1 (MX1),
and interferon-induced protein with tetratricopeptide repeats (IFIT5). The IFI44L and
MX1 transcripts were specifically among the top 5 transcripts identified, and the top 2 for
which a known function or pathway could be assigned.

Transfection with CLIC2
23

sequence C siRNA resulted in a reduction of IFI44L, MX1, and IFIT5 mRNAs relative to
transfection with CLIC2-U4A mutant siRNA as confirmed by qRT-PCR (Figure 2.5).

24

Figure 2.5. HAEC were transfected with CLIC2 sequence C and qRT-PCR was
used to quantify relative levels of IFI44L, MX1, and IFIT5 mRNA. Results indicate
that each of the three mRNAs was knocked down in the presence of CLIC2 sequence C,
but not in the presence of the mutated siRNA sequence.

To further investigate the interferon pathway which is a known modulator of viral
processes

58-60

, several knockdowns were conducted.

IFI44L, MX1, and IFIT5

knockdowns when tested individually did not result in an enhancement of AAV2-Luc
transduction (not shown), indicating that CLIC2 sequence C siRNA creates a complex
phenotype that results in enhanced transgene expression.

In an additional test of

interferon pathway processes, two unique siRNA sequences targeting the interferon
(alpha, beta, and omega) receptor 2 (IFNAR2) led to an increase in virus transduction
(Figure 2.6a).

In contrast, the addition of recombinant alpha interferon and beta

interferon directly into the cell culture at the time of transduction led to a decrease in
transgene expression (Figure 2.6b) with no change in cell viability (not shown).
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a

b

Figure 2.6. Effect of Type 1 interferons. (a) The addition of alpha interferon or beta
interferon leads to a dose-dependent decrease in AAV2 transduction. (b) Knockdown of
interferon (alpha, beta, omega) receptor 2 using two different siRNA sequences leads to
an increase in viral transduction.
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2.2.6. Human Airway Culture
We evaluated if the enhancing effect of CLIC sequence C siRNA was cell-specific by
testing enhancement of AAV2 transduction of a human bronchial epithelium. In order to
test the effectiveness of these siRNA sequences in a primary cell line, both the SLC5A2
sequence B and CLIC2 sequence C were evaluated in human bronchial epithelium using
adeno-associated virus type 2 coding for enhanced green fluorescent protein (EGFP),
followed by evaluation using fluorescence microscopy and flow cytometry.

At the

highest siRNA concentration tested, an increase in fluorescence of 27% was observed for
SLC5A2 sequence B and an increase in fluorescence of 61% was observed for CLIC2
sequence C (Figure 2.7). Although the siRNA sequences were identified using HAEC
cells, the results were not specific to the endothelium and may be useful for gene therapy
applications in respiratory diseases such as cystic fibrosis. These results also confirm that
the enhancing effects were not unique for the firefly luciferase reporter gene product
since SLC5A2 sequence B and CLIC2 sequence C siRNAs increased in fluorescence
from EGFP as measured using flow cytometry and were consistent with the luciferase
enhancements.
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Figure 2.7.
siRNA mediated enhancement of AAV2 transduction of human
epithelial cells. Fluorescence microscopy images and flow cytometry data for human
bronchial epithelium culture treated with (a) scrambled siRNA negative control, (b)
SLC5A2 sequence B and (c) CLIC2 siRNA sequence C and then transduced with AAV2
containing EGFP.
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2.2.7. Combination effects
Two experiments were carried out in which the effect of pair-wise combinations of
siRNAs was examined. The total siRNA concentration used was constant at 50 nM. In
the first of these experiments, pair-wise combinations of the top single siRNA sequence
for each of the top ten genes were examined (Figure 2.8a). In the second, pair-wise
combinations of the three siRNA sequences for the top three genes (CLIC2, GPR124, and
SLC5A2) were examined (Figure 2.8b). As expected, SLC5A2 sequence B and CLIC2
sequence C both provided high results both alone and in combination with other
sequences. GPR124 sequence B also provided a strong signal. In each of the two
experiments, the highest signal came from a mixture of two siRNA sequences.

For

example, GPR124 sequence A provided 2-fold improvement when used on its own, and
CLIC2 sequence C provided 4.3-fold improvement on its own, but the combination gave
5.6-fold improvement. The pairwise tests generally resulted in additive enhancement but
not synergistic enhancements.
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Figure 2.8. Pairwise interactions among confirmed siRNA hits. Heat map of
pairwise interactions between siRNA sequences (total siRNA concentration/well = 50
nM) for the top 10 confirmed hits (a) or the 3 different sequences against the top 3 hits
(b).
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2.2.8. Co-administration of siRNA with AAV
In order to examine the use of siRNA in combination with adeno-associated viral gene
delivery, two experiments were performed in which the siRNA was co-administered with
the viral vector. In the first, the virus was pre-mixed with the siPort/siRNA mixture and
then cells were added within thirty minutes (Figure 2.9a). In the second, the virus was
added immediately following the addition of cells to the siPort/siRNA mixture (Figure
2.9b). The main difference between these two experiments was the exposure of virus to a
higher concentration of siPort/siRNA for a short period of time in the pre-mixed
experiment. The experiments showed similar results to each other, and additionally
followed the same general trend of results observed for the standard transduction protocol
in which 24 hours elapsed between addition of siRNA and addition of virus. For the
SLC5A2 sequence B and CLIC2 sequence C sequences, increases in viral transduction in
the range of 50 to 150% were observed for the 50 nM condition.
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Figure 2.9. Coadministration of adeno-associated virus serotype 2 and short
interfering RNA (siRNA) to human aortic endothelial cells enhances transgene
expression. (a) Virus was premixed with siRNA lipoplexes and then added to cells. (b)
Cells were reverse transfected and virus was immediately added after adding cells to
siRNA formulation.
32

2.2.9. Common screening hits between Adenovirus and AAV2
Three primary screening hits were common to both an adenovirus screen and the AAV2
screen. These three hits were subject to a follow-up experiment. The top two out of
these, ARF GTPase-acting protein (GIT2) and Olfactory Receptor 51E1 (OR51E1), were
each screened using three novel siRNA sequences not present in the original screen. A
third,

phosphoribosylglycinamide

formyltransferase,

phosphoribosylglycinamide

synthetase, phosphoribosylaminoimidazole synthetase (GART), had previously been in
confirmatory studies using the original siRNA sequences from primary screening. This
third enhancer was retested using those original siRNA sequences. As demonstrated in
Figure 2.11, siRNA enhancement from these three genes was minimal.

Figure 2.10.
siRNA primary screening hits common to adenovirus and adenoassociated virus screens. Effect of GART, GIT, OR51E1 on AAV2 transduction of
HAEC, normalized to scrambled siRNA negative control.
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2.2.10. Serotype-Independence of Enhancement
In order to better understand the mechanism for enhancement of the top siRNA screening
hits, HAEC transfected with SLC5A2 sequence B or CLIC2 sequence C were then
transduced with either AAV2 or pseudotyped AAV2/1, which contains the AAV2
genome packaged into an AAV type 1 capsid. As demonstrated in Figure 2.11, the
siRNA enhancement was independent of the capsid selected.

Figure 2.11. Pseudotyped AAV2/1 vector shows similar transduction trends to
AAV2 vector. Cells treated with 50 nM siRNA were transduced with either AAV2 or
AAV2/1 at a multiplicity of infection of 10,000, followed by Bright-Glo Assay.
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2.3. Discussion
The use of siRNA high throughput screening targeting 5,520 genes allowed the
identification of enhancers of adeno-associated viral gene delivery.

By screening pools

of 3 siRNAs per targeted gene in triplicate, a stringent Robust Z-score > 4.75 provided
for a ~ 1 % hit rate. When individual siRNA sequences were retested, only 10 of the 50
targeted genes (20 % confirmation rate) resulted in AAV-Luc enhancements when the
siRNA sequences were tested individually (Figure 2.1). One of the strongest inducers
was the CLIC(C) sequence which had a beneficial action on transduction that was not
correlated to CLIC mRNA knockdown (Figure 2.3), indicating an off-target effect.
Inspection of a number of the confirmed siRNA sequences that enhanced transgene
expression led to the identification of a common hexamer seed region [5’-U2GUUUC73’] (Table 1). The U4A mutation in this hexamer seed region of the antisense strand
destroyed the enhancing activity of the CLIC(C) siRNA (Figure 2.4), indicating an
important role for off-target microRNA-like silencing as a mechanism enhancing AAV2
transduction. At present, no off-target silenced mRNAs have been identified that result in
the enhanced transduction. The off-target effects of siRNAs were beneficial to AAV2
transduction of both human endothelium and human bronchial epithelium (Figure 2.7).
Interestingly, siRNA sequences when used together provided additive benefits to AAV2
transduction (Figure 2.8) and never resulted in cross-antagonism (< 1-fold enhancement).
Several of the top mRNA levels that are down-regulated specifically by the CLIC(C)
siRNA sequence but not the CLIC(C)-U4A mutant siRNA were interferon-inducible
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genes (IFI44L, MX1, and IFIT5). Due to this result, the interferon pathway was further
explored and knockdown of the interferon (alpha, beta, omega) receptor 2 was shown to
improve transduction (Figure 2.6a). This receptor is activated by type I interferons. The
type I interferons serve as an early warning system in anti-viral defense. In response to a
stimulus from a pathogen, type I interferons are synthesized and secreted

60

. The type I

interferons then bind to receptors IFNAR1 or IFNAR2, and the janus kinase (JAK),
tyrosine kinases (Tyk2), and signal transducers and activators of transcription (STAT1
and STAT2) comprise the downstream pathways leading to production of interferoninduced proteins

58, 59, 61, 62

. Many proteins are induced by the interferons, although a

main pathway consists of the expression of protein kinase R (PKR). PKR then inhibits
protein synthesis by inducing RNAse L to destroy RNA and by activating eukaryotic
initiation factor 2 (eIF2) to lessen protein translation 63, 64. Other mechanisms additionally
recruit the adaptive immune response
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. Notably, a current literature search shows

several studies in which AAV has been used to deliver interferon-β for cancer gene
therapy 65-67. These studies show promising results; however the results presented in this
paper suggest that caution should be used when combining the AAV vector with
interferon, due to the potential that the interferon could inhibit future re-administration of
the vector.
With respect to therapeutic strategies to enhance transduction, we report that coadministration of siRNA lipoplexes with AAV2 results in enhanced transgene expression
(Figure 2.9), suggesting that the enhancement is due to siRNA-modulated pathways
distal of changes in receptor engagement, endocytosis, or endosome escape.

We
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conclude that siRNA sequences containing the hexamer seed region [5’-U2GUUUC7-3’]
result in a complex alteration of phenotype involving both translational silencing and
multiple off-target mRNA knockdowns that together modulate the interferon pathway
response to viral infection.

However in regard to gene therapy, this alteration of

phenotype can lead to enhancements in AAV transgene expression in human endothelium
and epithelial cells.
Although the GART, GIT, and OR51E1 genes appeared promising based on their
common appearance in hits from adenovirus and AAV2 screens, further study showed
limited enhancement from these genes (Figure 2.10).
Enhancement of the pseudotyped vector AAV2/1 by the top screening hits SLC5A2
sequence B and CLIC2 sequence C was comparable to enhancement by the AAV2 vector
(Figure 2.11). The only difference between these two vectors is the capsid and its
associated cellular receptors.

The primary receptor for AAV2 is heparan sulfate

proteoglycan, whereas the main receptor for AAV2/1 is sialic acid. This suggests that the
enhancement activity of these sequences is unrelated to virus/cell surface receptor
interaction.
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Chapter 3

3. Chemical Compound Screen
3.1. Abstract
A total of 2,320 molecules from two different chemical compound libraries were
screened for their ability to enhance adeno associated virus type 2 transduction of
cultured human endothelium. Of these compounds, 20 provided two-fold or greater
enhancement at a concentration of 10 µM in primary screening.

3.2. Introduction
The interaction of adeno-associated virus with a cell consists of a pathway which
includes surface receptor binding, endocytosis, endosomal escape, accumulation in the
perinuclear space, transport into the nucleus, capsids uncoating, the synthesis of the
second strand of DNA, transcription of the viral DNA to RNA, transport of the RNA out
of the nucleus, and translation of the RNA. In chapter 2, we discussed a high throughput
screen for the identification of siRNA enhancers of this process. In this chapter, we
adopted a high throughput screening approach to identify chemical compounds which
enhance the AAV2 transduction process. We then explore mechanistic details of selected
compounds.
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Cells were treated with compounds from the Sigma Library of Pharmacologically Active
Compounds (LOPAC) and National Institute of Neurological Disorders and Stroke
(NINDS) followed by addition of adeno-associated virus type 2 in order to identify
compounds which may enhance viral transduction. A total of 2,230 compounds were
screened.
20 compounds were identified as primary screening hits which enhanced viral
transduction greater than two-fold in primary screening.

These hits included several

families of compounds. Of those compound families, antioxidants, nucleoside analogs,
cell cycle arrestors, and alkylating agents were examined in more detail. Additionally,
metal chelation as a mechanism was investigated based on one of the top primary
screening hits.

3.3. Materials and Methods
3.3.1. Cell culture
Human Aortic Endothelial Cells (HAEC; Lonza, Walkersville, MD) were cultured in
supplemented Clonetics EGM-2 (Lonza, Walkersville, MD) at 37ºC and 5% CO2. Prior
to screening, cells were rinsed with Dulbecco’s phosphate-buffered saline and incubated
with 0.05% Trypsin-EDTA (Invitrogen, Santa Clara, CA), then seeded onto 384 well flat
bottom plates at a concentration of 860 cells per well in 15 ul of media (BD Bioscience,
Franklin Lakes, NJ).
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3.3.2. Compound libraries
The LOPAC (Sigma-Aldrich, Milwaukee, WI) and NINDS (Microsource Discovery
Systems, Gaylord, CT) libraries were used for screening.

LOPAC contains 1,280

chemicals at a concentration of 10 mM of compound suspended in 100% DMSO. The
NINDS library contains 1,040 chemicals at a concentration of 10 mM of compound
suspended in 100% DMSO.
A pin tool was used to transfer 0.1 microliters from the plates into a dilution plate
containing 25 ul of media, resulting in a final concentration of 40 µM of compound in
media. From these dilution plates, 5 ul of diluted compound was added to the cells in 15
ul of media, resulting in 20 ul of cells containing a concentration of 10 µM of compound.
The final DMSO concentration per well after compound was mixed with cells was 0.1%.
The cells were incubated in the presence of chemical compounds for 24 hours prior to the
addition of virus.
For further confirmation of screening results, chemicals were individually purchased
from Sigma (Milwaukee, WI) and dissolved in phosphate buffered saline if soluble in
aqueous solvents. Compounds that were not soluble in aqueous solvents were dissolved
in DMSO and subsequently added to cells in media such that the final DMSO
concentration was 1%. A list of specific compounds and catalog numbers investigated is
provided in the Appendix.
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3.3.3. Luciferase transduction protocol
Adeno-associated virus, type 2, containing a CMV promoter and firefly luciferase
sequence was added to the well plate at a multiplicity of infection of 10,000 viral genome
copies per cell. The virus was then allowed to transduce the cells for 24 hours. On the
fourth day following initial cell seeding, cells were assayed for gene expression using the
Bright-Glo assay kit (Promega, Madison, WI) following the vendor’s protocol.

3.3.4. Fluorescence transduction protocol
After 24 hours of exposure to chemicals, adeno-associated virus, type 2, containing a
CMV promoter and enhanced green fluorescent protein sequence was added to the plate.
The virus was allowed to transduce the cells for 24 hours and then the media containing
virus and chemicals was replaced with fresh media.

Microscopy images and flow

cytometry took place 24 hours after the media was replaced.

3.3.5. Flow Cytometry
An Accuri C6 Flow Cytometer (Accuri Cytometers, Ann Arbor, MI) was used for
quantitative analysis of individual cell fluorescence.

Cells were harvested into

Dulbecco’s Phosphate Buffered Saline (Invitrogen, Santa Clara, CA) and then held on ice
until measurement. 20,000 counts per sample were recorded.
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3.3.6. Cell viability assay
Cells were assayed for viability using the Cell Titer Glo assay kit (Promega, Madison,
WI) following the vendor’s protocol.

3.3.7. Total Protein Quantification
The total amount of protein present in the sample was measured by BCA assay. Cells
were released from the well plate using 0.25% Trypsin followed by the addition of media.
They were then centrifuged to create a pellet which was washed with saline followed by
the addition of lysis buffer containing 100 mM potassium phosphate, pH 7.8 and 2%
Triton-X 100. Cells were incubated in lysis buffer for 40 minutes prior to BCA assay.
The assay was conducted according to manufacturer’s instructions using the Pierce BCA
Assay Kit (Thermo Scientific, Rockford, IL).

3.3.8. DNA Purification
Cells treated with compound followed by AAV2-EGFP were then harvested two days
later for total DNA content using the DNeasy Blood & Tissue Kit kit (Qiagen, Valencia,
CA).
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3.3.9. cDNA Synthesis
Cells treated with compound followed by AAV2-EGFP were then harvested two days
later for total RNA content using the Absolutely RNA microprep kit (Stratagene, La
Jolla, CA). Superscript III reverse trasnscriptase and oligo(dT) (Invitrogen, Carlsbad,
CA) were used to reverse transcribe the RNA, resulting in cDNA.

3.3.10. Quantitative Real Time PCR
Purified DNA and synthesized cDNA were then amplified using the Roche LightCycler
(Roche, Indianapolis, IN). LightCycler FastStart DNA MasterPLUS SYBR Green I kit
(Roche, Indianapolis, IN) and Light Cycler melting curve analysis was used to perform
quantitative real-time PCR.

The EGFP DNA was measured using forward primer

CGACAACCACTACCTGAGCA
GAACTCCAGCAGGACCATGT.

and

the

reverse

primer

GAPDH DNA or cDNA was used to normalize

between samples according to the sample type used. The GAPDH forward primer and
reverse

primers

were,

respectively,

TGCACCACCAACTGCTTAGC

and

the

GGCATGGACTGTGGTCATGAG.
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3.4. Results
3.4.1. Primary screening
2,320 compounds from the two screening libraries were examined for the effect of each
chemical compound on AAV2 transduction of cultured human aortic endothelial cells.
Cells were transferred into 384 well culture plates, and one day later chemicals dissolved
in DMSO were transferred into each well such that the final concentration of DMSO in
each well was 0.1%. On the next day, the HAEC were transduced with AAV2 coding for
the firefly luciferase gene (AAV2-Luc) at 8.60 x 106 genome copies per well and the
luciferase was then assayed 24 hours post-transduction (Figure 3.1a). These compounds
are listed in Appendix 1. The Robust Z-factor

53, 57

provides a metric of the median

absolute deviation by which an individual chemical (averaged over 2 replicates) differs
from the population median. Figure 3.1b below shows representative data for a single
plate as well as the Z-score plot of the two replicates. Compounds with Z-score greater
than 3 for both replicates are included in the box at the top right of the figure.
Compounds with Z-score less than -3 were not found.
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Figure 3.1.
Chemical compound primary screening results. a: Results for a
representative 384 well plate. Hits of three standard deviations above the mean for the
plate are circled in red. b: Overall primary screening results.
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The top hits from primary screening were further examined through the individual
addition of these compounds to cells in 96 well plates. The most promising compounds
from that work, as well as related compounds, were examined in more detail, including
dose-response testing and viability testing.
From the primary screening results, it appeared that several families of related
compounds emerged as hits.

Ellagic acid, caffeic acid phenethyl ester, 7,4-

dihydroxyflavone, daidzein, resveratrol, and 7,2-dihydroxyflavone are all antioxidant
compounds.68 Tyrphostin AG 698, Tyrphostin AG 490, and Tyrphostin AG 537 are all
EGFR protein tyrosine kinase inhibitors.

4,5-dianiliophthalamide is additionally a

protein tyrosine kinase inhibitor. Cell cycle arrestors were also examined due to the cell
cycle regulatory effects of daidzein and 1,10-phenanthroline. 5-bromo-2-deoxyuridine,
vidarabine, and 3-azido-3-deoxythymidine are all nucleoside analogs. Carboplatin and
melphalan are both alkylating agents. As previous reports had investigated EGFR protein
tyrosine kinase inhibitors in detail,69,

70

we chose to focus on antioxidants, nucleoside

analogs, and alkylating agents. Additionally, as the metal chelator 1,10-phenanthroline
provided a very strong signal in primary screening, we also included metal chelators in
our investigation.

3.4.2. Mechanistic Studies
In order to probe the mechanism for several of the top hits, cells were treated with 10 µM
of compound and transduced with AAV-EGFP 24 hours later. After 48 hours, cells were
examined by fluorescence microscopy, flow cytometry, PCR for quantification of EGFP
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DNA, qRT-PCR for quantification of EGFP RNA, and BCA assay for quantification of
total cellular protein. Results are given in Table 3.1 below.

1% DMSO*
Ellagic acid*
Tyrphostin 698*
Melphalan*
Vidarabine
5-bromo-2'deoxyuridine
1,10-phenanthroline
Carboplatin
MOI 0 (no virus)
MOI 1,000
MOI 10,000
MOI 100,000

Normalized
Virus DNA
(EGFP)
1.0
1.0
0.2
0.6
0.7
0.8

Normalized
Virus RNA
(EGFP)
1.0
61.1
0.5
2.7
2.8
5.1

1.9
1.0
0.0
0.1
1.0
10.0

4.6
1.7
0.0
0.2
1.0
2.0

Normalized Normalized
Average
Total
Fluorescence
Protein
1.0
1.0
33.4
2.0
2.0
1.0
2.6
1.7
1.4
0.6
2.3
0.8
2.3
1.2
0.1
0.2
1.0
1.5

0.9
0.7
1.0
1.0
1.0
0.8

Table 3.1. Normalized viral DNA, viral RNA, average fluorescence per cell, and total
protein per well for selected compounds. For RNA and DNA measurements, the ratio of

EGFP signal to GAPDH signal is calculated for each sample, and then that ratio is
normalized to control. Conditions with an asterisk (*) contained 1% DMSO in the well
and were normalized to the DMSO control. All other conditions are normalized to the
MOI 10,000 sample.

3.4.3. Tyrosine kinase inhibitors
Three of the compounds found (Tyrpohstin AG 490, Tyrphostin AG 537, and Tyrphostin
AG 698) are epidermal growth factor receptor (EGFR) protein tyrosine kinase inhibitors.
EGFR is a cell surface receptor which when activated by ligand homodimerizes, forming
a kinase on the internal surface of the cell membrane. It autophosphorylates and serves
as a kinase for several other pathways.71 Consistent with these results, previous work by
Zhong and colleagues has shown that the addition of the EGFR protein tyrosine kinase
47

inhibitor Tyrphostin 23 increased AAV2 transduction.

They found two specific

mechanisms by which EGFR inhibition enhanced transduction; through decreased
ubiquination of AAV2 capsids and through decreased FK506-binding protein inhibition
of AAV2 second-strand DNA synthesis.70 The existence of many EGFR protein tyrosine
kinase inhibitors on the list of primary screening hits supports the finding that EGFR
inhibition enhances transduction, and as shown in Table 3.1, reporter gene expression is
increased when Tyrphostin 698 was exposed to cells. However, because previous reports
investigated the effect of EGFR protein tyrosine kinase inhibitors in great detail, the
current work did not study these compounds in depth.

3.4.4. Antioxidants
Several antioxidant compounds were identified in primary screening, including ellagic
acid, caffeic acid phenethyl ester, 7,4-dihydroxyflavone, and 7,2-dihydroxyflavone.
Ellagic acid was of particular interest as it was the strongest hit in primary screening and
it continued to perform well in follow-up studies (Figure 3.2 and Figure 3.3). In order
to follow-up on the success of ellagic acid as an enhancer, other compounds with similar
functionality were examined. Caffeic acid, an antioxidant which demonstrated some
enhancement during primary screening, showed poor performance in a dose-response
curve (Figure 3.4a). Ascorbic acid (vitamin C) was added to growth media, but no
enhancement of viral transduction was observed (Figure 3.5). N-acetyl cysteine was also
added with no enhancement of viral transduction (Figure 3.6). Other anti-oxidants
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including beta-carotene and bilirubin were also examined, but poor solubility in DMSO
or aqueous solution prevented their experimental use (data not shown).
Although ellagic acid is primarily considered as an antioxidant compound, it also serves
as a tyrosine protein kinase inhibitor, can induce cell cycle arrest, and has intercalating
properties.72-75 Due to the inability of other antioxidant compounds to facilitate adenoassociated virus transduction, it appears that the enhancement effect of ellagic acid is
likely due to other effects.

3.4.4.1.

Ellagic Acid

Ellagic acid was the top hit in primary screening and continued to perform well in doseresponse studies (Figure 3.2a). Ellagic acid showed an impressive level of enhancement
in high throughput screening, and it continued to show dose-dependent enhancement
during follow-up studies. However, ellagic acid also demonstrated limitations, primarily
in solubility and toxicity. Dissolution of ellagic acid at concentrations up to 10 mM in
either DMSO or aqueous solution was extremely challenging, and most studies were
performed by dissolving ellagic acid directly in media and replacing the growth media in
the well with filtered growth media containing ellagic acid at the required concentration.
Differences in enhancement and toxicity between experimental runs may have been due
to variability caused by the difficulty in dissolving ellagic acid at the required
concentration.
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a)

b)
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c)

Figure 3.2 Ellagic acid luciferase assay and viability results. a) Ellagic acid was
dissolved at a concentration of 100 µM in media, serially diluted in media, and added to
HAEC. 24 hours later, adeno-associated virus was added, followed by luciferase assay
after another 24 hours. b) Normalized cell viability following 48 hours of cell exposure
to ellagic acid dissolved in media. c) AAV serotype 2, 2/1, and 2/9 were added to HAEC
following treatment with ellagic acid.

HAEC treated with 10 µM ellagic acid were additionally subject to transduction with
AAV2-EGFP and examined using fluorescence microscopy, PCR, qRT-PCR, flow
cytometry, and BCA assay. As shown in Table 3.1, the amount of viral DNA measured
in the cell was the same as the 1% DMSO control, whereas viral RNA and fluorescence
was greatly increased (61 fold change and 33 fold change, respectively). The total
protein per well as measured by BCA assay increased two-fold.
Because the viral RNA and fluorescence levels changed so dramatically, the PCR data
was examined more closely for insight into mechanism to determine whether this result
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was a global increase in protein level or restricted to the increase in viral RNA and
reporter gene signal (Table 3.2). The increase in GAPDH RNA and the large normalized
GAPDH RNA/GAPDH DNA value, in combination with the two-fold increase in protein
quantity by BCA assay, suggests that the results may be related to a global increase in
overall protein. A previous report also described an increase in GAPDH mRNA and total
protein levels as a result of ellagic acid exposure.75

1% DMSO*
Ellagic acid*
Tyrphostin 698*
Melphalan*
Vidarabine
5-bromo-2'deoxyuridine
1,10-phenanthroline
Carboplatin
MOI 0 (no virus)
MOI 1,000
MOI 10,000
MOI 100,000

GAPDH
DNA
1.0
0.8
3.3
0.9
4.3
2.2

GAPDH RNA
(from cDNA)
1.0
8.3
0.4
0.01
0.1
0.3

GAPDH RNA/
GAPDH DNA
1.0
9.7
0.1
0.02
0.03
0.1

0.7
1.1
4.3
1.9
1.0
1.3

0.1
0.8
0.7
1.1
1.0
0.1

0.1
0.7
0.2
0.6
1.0
0.1

Table 3.2 Normalized values for quantitative real time PCR measurement of GAPDH DNA,
GAPDH RNA (by measurement of cDNA), and the ratio of RNA/DNA. Compounds

indicated with an asterisk have been normalized by the 1% DMSO measurement,
whereas others were normalized by the MOI 10,000 condition.
Figure 3.3 provides corresponding information for fluorescence microscopy and flow
cytometry. As compared with the 1% DMSO control, the cells treated with ellagic acid
are elongated and much more fluorescent (Figure 3.3a,b). Flow cytometry showed more
granularity in ellagic acid treated cells, as indicated by an increased side scatter
measurement (Figure 3.3c,d). An overlay of the fluorescence clearly shows that the
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ellagic acid treated cells have much higher levels of fluorescence following transduction
with AAV2-EGFP (Figure 3.3e).

Figure 3.3. Fluorescence microscopy images and flow cytometry data for HAEC
treated with ellagic acid followed by AAV2-EGFP transduction. a. Image of HAEC
treated with 1% DMSO followed by AAV2-EGFP. b. Image of HAEC treated with
ellagic acid in 1% DMSO followed by AAV2-EGFP. c. Forward and side scatter results
for HAEC treated with 1% DMSO followed by AAV2-EGFP from flow cytometry. d.
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Forward and side scatter results for HAEC treated with ellagic acid in 1% DMSO
followed by AAV2-EGFP from flow cytometry. e. Histogram overlay of fluorescence
area for HAEC treated with 1% DMSO (black) and ellagic acid in 1% DMSO followed
by HAEC treated with AAV2-EGFP (red).

3.4.4.2.

Caffeic Acid Phenethyl Ester

Caffeic acid demonstrated a 2.5 fold enhancement in primary screening (Appendix
Table A4) and was therefore examined more closely for a dose response. Additionally,
caffeic acid phenethyl ester is an antioxidant compound, which allowed further probing
of the potential for antioxidants to serve as a class of enhancing molecules.76 Figure 3.4a
below shows that the compound only moderately benefited viral transduction, while
Figure 3.4b demonstrates that cell viability was unaffected by the virus.
a)
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b)

Figure 3.4. Caffeic acid phenethyl ester results. a) Caffeic acid phenethyl ester was
dissolved at a concentration of 10 mM in DMSO, serially diluted in DMSO, and added to
HAEC cells in media such that the final DMSO concentration in each well was 1%. 24
hours later, adeno-associated virus was added, followed by luciferase assay after another
24 hours. b) Viability of HAEC following 48 hours of exposure to caffeic acid dissolved
in DMSO.

3.4.4.3.

Ascorbic acid

In order to further examine antioxidant functions, ascorbic acid (vitamin C) was added to
cells followed by treatment with virus containing the luciferase reporter gene. As shown
in Figure 3.5 below, the addition of ascorbic acid had no effect on viral transduction.
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Figure 3.5. Ascorbic acid luciferase assay dose response results. Ascorbic acid was
dissolved at a concentration of 100 µM in media, serially diluted in media, and added to
HAEC. 24 hours later, adeno-associated virus was added, followed by luciferase assay
after another 24 hours.

3.4.4.4.

N-acetyl cysteine

N-acetyl cysteine is another antioxidant compound.77 It was additionally tested in order
to probe possible antioxidant enhancement of AAV2 transduction.

The compound

appears to have a moderate effect at best, most likely explained by an artifact of the
experimental procedure (edge effects), as shown in Figure 3.6.
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Figure 3.6. N-acetyl cysteine luciferase assay dose-response results. N-acetyl cysteine
was dissolved at a concentration of 100 µM in media, serially diluted in media, and added
to HAEC. 24 hours later, adeno-associated virus was added, followed by luciferase assay
after another 24 hours.

3.4.5. Metal Chelators
1,10-phenanthroline is a metal chelator which was one of the top hits identified in the
primary screen.

1,10-phenanthroline was examined in more detail.

ethylenediaminetetraacetic acid

Additionally,

(EDTA), a commonly used metal chelator, was

examined to see if enhancement would be observed in other metal chelators.

3.4.5.1.

1,10-phenanthroline

1,10 phenanthroline is a metal chelator which inhibits metalloproteases and additionally
activates p53 transcriptional activity.78 1,10-phenanthroline was the second strongest hit
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identified in primary screening, with a normalized luminescence value of 6.4 (Appendix
table A4). Although this compound was capable of providing significant enhancement, it
was also demonstrated to be toxic to HAEC at values above 3 uM, which explains the
sharp drop in reported enhancement at high compound doses (Figure 3.7b). 1,10phenanthroline enhanced adeno-associated viral transduction for pseudotyped viruses
AAV2/1 and AAV2/9, suggesting that the response to compound is independent of cell
surface receptor binding (Figure 3.7c).
a)

58

b)

c)

Figure 3.7. Luciferase assay and viability results for HAEC treated with 1,10phenanthroline. a) 1,10 phenanthroline luciferase assay results. 1,10 phenanthroline
was dissolved at a concentration of 10 mM in DMSO, serially diluted in DMSO, and
added to HAEC cells in media such that the final DMSO concentration in each well was
1%. 24 hours later, adeno-associated virus was added, followed by luciferase assay after
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another 24 hours. b) HAEC viability following 48 hours exposure to 1,10 phenanthroline
dissolved in DMSO. c) Luciferase assay results for HAEC exposed to 1,10phenanthroline followed by AAV2, AAV2/1, or AAV2/9. Two 1,10-phenanthroline
concentrations were measured.
HAEC treated with 10 µM 1,10-phenanthroline were additionally subject to transduction
with AAV2-EGFP and examined using fluorescence microscopy, PCR, qRT-PCR, flow
cytometry, and BCA assay. As shown in Table 3.1, the amount of viral DNA measured
was two-fold higher than in the control sample. Viral RNA present was additionally
increased to 4.6 times greater than control, and the average fluorescence was 2.3 times
higher than in the control. The total protein in the well was about the same as the control.
Figure 3.8 provides corresponding information for fluorescence microscopy and flow
cytometry. Cells treated with the 1,10-phenanthroline do not show a large morphological
change as determined by microscopy or by flow cytometry (Figure 3.8a,b,c,d). An
overlay of the fluorescence data shows the overall fluorescence profile shifting to the
right in addition to the appearance of a small group of very highly fluorescent cells.
(Figure 3.8e).
Overall, the data suggest that 1,10-phenanthroline does not affect the virus/receptor
interaction due to the non-serotype specificity, however DNA levels are increased.
Therefore, it is possible that 1,10 phenanthroline may be protecting the virus from
degradation during endosome processing, perhaps by interfering with metalloproteases.
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Figure 3.8. Fluorescence microscopy images and flow cytometry data for HAEC
treated with 1,10 phenanthroline followed by AAV2-EGFP transduction. a. Image
of HAEC transduced with AAV2-EGFP. b. Image of HAEC treated with 1,10phenanthroline followed by AAV2-EGFP transduction. c. Forward and side scatter
results for HAEC transduced with AAV2-EGFP from flow cytometry. d. Forward and
side scatter results for HAEC treated with 1,10-phenanthroline followed by AAV2-EGFP
from flow cytometry. e. Histogram overlay of fluorescence area for HAEC treated with
AAV2-EGFP (black) and HAEC treated with 1,10-phenanthroline followed by AAV2EGFP (red).
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3.4.5.2.

Ethylenediaminetetraacetic acid (EDTA)

An alternative metal chelator, ethylenediaminetetraacetic acid

(EDTA), was examined

and found to have no effect on viral transduction, leading to the conclusion that 1,10phenanthroline’s effect on viral enhancement is not general to all metal chelators,
although it is possible that it may be specific to a subclass of metal chelators such as zinc
chelators.

Figure 3.9. EDTA luciferase assay dose response results. EDTA was dissolved at a
concentration of 100 µM in media, serially diluted in media, and added to HAEC. 24
hours later, adeno-associated virus was added, followed by luciferase assay after another
24 hours.
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3.4.6. Alkylating Agents
Carboplatin, cisplatin, and melphalan all provided dose-dependent enhancement of
adeno-associated virus transduction of HAEC. At high concentrations, both cisplatin and
melphalan showed a decrease in luminescence signal which was explained by the toxicity
of these compounds at high concentrations. Based on these results, it appears that DNA
alkylation is a mechanism for increased adeno-associated virus transduction. Russel,
Alexander, and Miller demonstrated that treating cells with radiation or DNA-damaging
chemicals enhanced adeno-associated virus transduction, and our results corroborate
those findings.18, 79, 80

3.4.6.1.

Carboplatin

Carboplatin, an alkylating agent, was found to have a dose-dependent enhancement of
adeno-associated virus activity.

Carboplatin demonstrated a 2.5 fold increase in

transduction efficiency in primary screening (Appendix Table A4).

Carboplatin

dissolved in DMSO led to an enhancement of up to 7 fold at high concentrations with an
EC50 based on all available data of about 50 µM (Figure 3.10a). When dissolved in
media and filtered, carboplatin’s enhancement activity was more limited, with a
maximum enhancement of about 2 fold. (Figure 3.10b). This discrepancy may be due to
an effect of DMSO or due to limitations of compound solubility in aqueous solution.
Although the compound is commonly known to be toxic due to its DNA alkylation
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activity, no viability changes were observed in a dose-response assay over this range
(Figure 3.10c, d).
a)

b)
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c)

d)
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e)

Figure 3.10. Carboplatin results. a) Carboplatin was dissolved at a concentration of 10
mM in DMSO, serially diluted in DMSO, and added to HAEC cells in media such that
the final DMSO concentration in each well was 1%. 24 hours later, adeno-associated
virus was added, followed by luciferase assay after another 24 hours. b) Carboplatin was
dissolved at a concentration of 10 mM in media, serially diluted in media, and added to
HAEC cells in media. 24 hours later, adeno-associated virus was added, followed by
luciferase assay after another 24 hours. c) HAEC viability after 48 hours of exposure to
carboplatin dissolved in DMSO, normalized to DMSO control. d) HAEC viability after
48 hours of exposure to carboplatin dissolved in media. e) Luciferase assay results for
HAEC exposed to carboplatin followed by treatment with AAV2, AAV2/1, or AAV2/9.
HAEC treated with 10 µM carobplatin were additionally subject to transduction with
AAV2-EGFP and examined using fluorescence microscopy, PCR, qRT-PCR, flow
cytometry, and BCA assay. As shown in Table 3.1, the amount of viral DNA was the
same as the control sample, although viral RNA present was increased by a factor of 1.7.
The average fluorescence was 20% higher than in the control. The total protein in the
well was less than the control. Figure 3.11 provides corresponding information for
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fluorescence microscopy and flow cytometry. Cells treated with the carboplatin do not
show a large morphological change as determined by microscopy or by flow cytometry
(Figure 3.11a,b,c,d). An overlay of the fluorescence data shows the overall fluorescence
profile shifting slightly to the right. (Figure 3.11e).
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Figure 3.11. Fluorescence microscopy images and flow cytometry data for HAEC
treated with carboplatin followed by AAV2-EGFP transduction. a. Image of HAEC
transduced with AAV2-EGFP. b. Image of HAEC treated with carboplatin followed by
AAV2-EGFP transduction. c. Forward and side scatter results for HAEC transduced with
AAV2-EGFP from flow cytometry. d. Forward and side scatter results for HAEC treated
with carboplatin followed by AAV2-EGFP from flow cytometry. e. Histogram overlay
of fluorescence area for HAEC treated with AAV2-EGFP (black) and HAEC treated with
carboplatin followed by AAV2-EGFP (red).

3.4.6.2.

Cisplatin

Cisplatin, a compound highly related to carboplatin, was also tested and found to be
beneficial for viral transduction. Alexander and colleagues previously reported that
cisplatin facilitates adeno-associated virus transduction.79 Cisplatin is a very similar
compound to carboplatin. It was evaluated in order to determine if enhancement due to
carboplatin was due to the bidentate carboxylate group of the carboplatin or due to the
cis-diammine platinum portion of the molecule which it has in common with cisplatin.
As shown in Figure 3.12a, cisplatin is also capable of enhancing viral transduction, with
enhancement of nearly 4-fold at its peak. However, as shown in Figure 3.12b, toxic
effects begin to be seen between 10 and 100 uM, limiting cisplatin’s effectiveness.
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a)

b)

Figure 3.12. Cisplatin results. a) Cisplatin was dissolved at a concentration of 10 mM
in media, serially diluted in media, and added to HAEC cells in media. 24 hours later,
adeno-associated virus was added, followed by luciferase assay after another 24 hours.
b) Cell viability after 48 hours of exposure to cisplatin.
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3.4.6.3.

Melphalan

Melphalan is another DNA alkylating agent which caused enhancement in primary
screening, with the observed enhancement of 2.1 fold. In subsequent dose-response
experiments, melphalan was capable of enhancement of up to 5-fold, although at high
concentrations toxicity was observed (Figure 3.13a,b).
a)
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b)

c)

Figure 3.13. Melphalan luciferase assay and viability results. a) Melphalan was
dissolved at a concentration of 10 mM in DMSO, serially diluted in DMSO, and added to
HAEC cells in media such that the final DMSO concentration in each well was 1%. 24
hours later, adeno-associated virus was added, followed by luciferase assay after another
24 hours. b) Cell viability after 48 hours of exposure to melphalan dissolved in DMSO. c)
Luciferase assay results for HAEC exposed to melphalan followed by exposure to AAV2,
AAV2/1, or AAV2/9.
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HAEC treated with 10 µM melphalan were additionally subject to transduction with
AAV2-EGFP and examined using fluorescence microscopy, PCR, qRT-PCR, flow
cytometry, and BCA assay. As shown in Table 3.1, the amount of viral DNA measured
in the cell was less than in the 1% DMSO control, whereas viral RNA and fluorescence
were each increased greater than two-fold (2.7 and 2.6 fold, respectively). The total
protein per well as measured by BCA assay increased by 70%. Figure 3.14 provides
corresponding information for fluorescence microscopy and flow cytometry.

As

compared with the 1% DMSO control, the cells treated with melphalan appear to have a
small highly fluorescent population (Figure 3.14a,b).

Flow cytometry showed no

morphological changes between cells treated with melphalan and those treated with
DMSO only (Figure 3.14c,d). An overlay of the fluorescence data shows that the
fluorescence profile of the melphalan treated cells is shifted to the right slightly in
comparison with the 1% DMSO only treated cells (Figure 3.14e).
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Figure 3.14. Fluorescence microscopy images and flow cytometry data for HAEC
treated with melphalan followed by AAV2-EGFP transduction. a. Image of HAEC
treated with 1% DMSO followed by AAV2-EGFP. b. Image of HAEC treated with
melphalan in 1% DMSO followed by AAV2-EGFP. c. Forward and side scatter results
for HAEC treated with 1% DMSO followed by AAV2-EGFP from flow cytometry. d.
Forward and side scatter results for HAEC treated with melphalan in 1% DMSO
followed by AAV2-EGFP from flow cytometry. e. Histogram overlay of fluorescence
area for HAEC treated with 1% DMSO (black) and melphalan in 1% DMSO followed by
HAEC treated with AAV2-EGFP (red).
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3.4.7. Nucleoside Analogs
Three of the compounds (5-bromo-2-deoxyuridine, vidarabine, and AZT ) identified in
primary screening are nucleoside analogs which are incorporated during DNA synthesis.
Two of the three are often used as anti-viral drugs. AZT is well-known as a reverse
transcriptase inhibitor for HIV treatment, and vidarabine is used for several different
virus types.

The third compound, 5-bromo-2-deoxyuridine, is most often used for

molecular biology experiments as a way to study DNA synthesis. It is important to note
that the engineered AAV2 is a single-stranded DNA virus that is not replication
competent, and therefore some mechanisms that interfere with viral replication (for
example, reverse transcriptase inhibition) should not affect this virus. However, the
evidence here that these nucleoside analogs enhance AAV2 transduction was initially
surprising. However, these results do fit with the findings of previous researchers that
DNA damage enhances AAV2 transduction.18, 79, 80
Four nucleoside analogs were examined in this study.

Three of the four were

reproducibly found to be beneficial for viral transduction and were well-tolerated in
viability assays. Overall, it appears that the addition of nucleoside analogs assists in the
viral transduction of adeno-associated virus.
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3.4.7.1.

Azidothymine (AZT)

Azidothymine (AZT) is a nucleoside analog commonly used as an HIV reverse
transcriptase inhibitor which demonstrated viral enhancement of 2.2 fold in primary
screening (Appendix Table A4). As shown in Figure 3.15, AZT demonstrated at most a
moderate enhancement in dose-response testing, which may be due to experimental
artifact (well plate edge effects). Although AZT did not demonstrate enhancement in
dose-response studies presented here, in preliminary work it demonstrated enhancement
of up to 2.5-fold (data not shown), suggesting that limitations of the compound’s stability
may have led it to be less effective during later experiments.

Figure 3.15. Azidothymine (AZT) luciferase results. AZT was dissolved at a
concentration of 10 mM in media, serially diluted in media, and added to HAEC cells in
media. 24 hours later, adeno-associated virus was added, followed by luciferase assay
after another 24 hours.

75

3.4.7.2.

Adenine 9-beta-d-arabinofuranoside (Vidarabine)

Adenine 9-beta-d-arabinofuranoside (vidarabine) is a nuceloside analog which
demonstrated a 2.4 fold increase in viral transduction in primary screening
(Supplementary Table S3). In dose-response testing, vidarabine showed enhancement of
up to three-fold at high concentrations, with an EC50 of about 16 µM (Figure 3.16).
a)
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b)

c)

Figure 3.16. Vidarabine luciferase and viability results. a) Vidarabine was dissolved
at a concentration of 10 mM in media, serially diluted in media, and added to HAEC cells
in media. 24 hours later, adeno-associated virus was added, followed by luciferase assay
after another 24 hours. b) HAEC viability following 48 hours of exposure to vidarabine.
c) Luciferase assay results for HAEC exposed to vidarabine followed by addition of
AAV2, AAV2/1, or AAV2/9.
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HAEC treated with 10 µM vidarabine were additionally subject to transduction with
AAV2-EGFP and examined using fluorescence microscopy, PCR, qRT-PCR, flow
cytometry, and BCA assay. As shown in Table 3.1, the amount of viral DNA was less
than in the control sample, although viral RNA present was increased by a factor of 2.8.
The average fluorescence was 40% higher than in the control. The total protein in the
well was less than the control. Figure 3.17 provides corresponding information for
fluorescence microscopy and flow cytometry. Cells treated with the vidarabine do not
show a large morphological change as determined by microscopy or by flow cytometry
(Figure 3.17a,b,c,d). An overlay of the fluorescence data shows the overall fluorescence
profile shifting slightly to the right. (Figure 3.17e).
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Figure 3.17. Fluorescence microscopy images and flow cytometry data for HAEC
treated with vidarabine followed by AAV2-EGFP transduction. a. Image of HAEC
transduced with AAV2-EGFP. b. Image of HAEC treated with 10 µM vidarabine
followed by transduction with AAV2-EGFP. c. Forward and side scatter results for
HAEC transduced with AAV2-EGFP from flow cytometry. d. Forward and side scatter
results for HAEC treated with 10 µM vidarabine followed by transduction with AAV2EGFP from flow cytometry. e. Histogram overlay of fluorescence area for HAEC
transduced with AAV2-EGFP (black) and 10 µM vidarabine followed by HAEC treated
with AAV2-EGFP (red).
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3.4.7.3.

Cytosine arabinofuranoside (Cytarabine)

Based on the high representation of nucleoside analogs as primary screening hits, a
related compound, cytarabine (cytosine beta-d-arabinofuranoside), was additionally
examined.

This compound is a cysteine analog.

Cytarabine was examined as a

nucleoside analog not identified in primary screening to validate the ability of this class
of chemicals to provide enhancement. Cytarabine showed an increase of nearly 4-fold
enhancement at higher doses, with an EC50 of about 16 µM (Figure 3.18a).
a)
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b)

Figure 3.18. Cytarabine luciferase and viability results. a) Cytarabine was dissolved
at a concentration of 10 mM in media, serially diluted in media, and added to HAEC cells
in media. 24 hours later, adeno-associated virus was added, followed by luciferase assay
after another 24 hours. b) HAEC viability following 48 hours of exposure to cytosine
arabinofuranoside.

3.4.7.4.

5-bromo-2’-deoxyuridine

5-bromo-2’-deoxyuridine is a nucleoside analog which was identified as an enhancer at
the level of 2.6 fold enhancement in primary screening (Appendix Table A4). In doseresponse testing, 5-bromo-2’-deoxyuridine showed continuous increase in enhancement
activity of over 4-fold enhancement at the maximum concentration tested of 100 µM
(Figure 3.19a). The EC50 for this compound is above 50 µM.
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a)

b)
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c)

Figure 3.19. 5-bromo-2’-deoxyuridine luciferase and viability results. a) 5-bromo2’-deoxyuridine was dissolved at a concentration of 10 mM in media, serially diluted in
media, and added to HAEC cells in media. 24 hours later, adeno-associated virus was
added, followed by luciferase assay after another 24 hours. b) HAEC viability following
48 hours of exposure to 5-bromo-2’-deoxyuridine. c) Luciferase assay results for HAEC
treated with 5-bromo-2’-deoxyuridine followed by addition of AAV2, AAV2/1, or
AAV2/9.
HAEC treated with 10 µM

5-bromo-2’-deoxyuridine were additionally subject to

transduction with AAV2-EGFP and examined using fluorescence microscopy, PCR,
qRT-PCR, flow cytometry, and BCA assay. As shown in Table 3.1, the amount of viral
DNA was the less than in the control sample, although viral RNA present was increased
by over five-fold.

The average fluorescence was more increased more than 2 fold

compared to control. The total protein in the well was less than the control. Figure 3.20
provides corresponding information for fluorescence microscopy and flow cytometry.
Cells treated with the 5-bromo-2’-deoxyuridine do not show a large morphological
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change as determined by microscopy or by flow cytometry (Figure 3.20a,b,c,d). An
overlay of the fluorescence data shows more cells exhibiting fluorescence at the very
high end of the spectrum. (Figure 3.20e).

Figure 3.20. Fluorescence microscopy images and flow cytometry data for HAEC
treated with 5-bromo-2’-deoxyuridine followed by AAV2-EGFP transduction. a.
Image of HAEC transduced with AAV2-EGFP. b. Image of HAEC treated with 10 µM
5-bromo-2’-deoxyuridine followed by transduction with AAV2-EGFP. c. Forward and
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side scatter results for HAEC transduced with AAV2-EGFP from flow cytometry. d.
Forward and side scatter results for HAEC treated with 10 µM 5-bromo-2’-deoxyuridine
followed by transduction with AAV2-EGFP from flow cytometry. e. Histogram overlay
of fluorescence area for HAEC transduced with AAV2-EGFP (black) and 10 µM 5bromo-2’-deoxyuridine followed by HAEC treated with AAV2-EGFP (red).

3.4.8. Cell Cycle Arrestors
1,10-phenanthroline, although cytotoxic, has been shown to increase transcription and
activity of p53.78 p53 serves many antitumorigenic roles within the cell, one of which is
to temporarily arrest the cell cycle in the G1 phase.81

Daidzein, which also halts

progression of the cell cycle past G1, is another chemical which enhanced transduction in
the compound screen. Previous reports have shown that the S-phase of the cell cycle is
more permissive to viral transduction, so it is interesting that these compounds arrest the
cell cycle in G1 rather than in S-phase.
The mechanism of action of these compounds for enhancement of viral transduction may
therefore be unrelated to their cell cycle arresting activity, especially in light of the
minimal enhancement activity demonstrated by NU 2058.

3.4.8.1.

NU 2058

NU 2058 inhibits cyclin-dependent kinase 1 and cyclin-dependent kinase 2.82 It was
examined in order to evaluate the ability of cell cycle arrestors to enhance viral
transduction, as inhibition of these kinases restricts the cell’s ability to move from G1

85

into S phase. NU 2058 showed limited enhancement in dose-response testing. (Figure
3.21).

Relative Luminescence Units
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2
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1.5
1
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Figure 3.21: NU 2058 luciferase assay results. NU2058 was dissolved at a
concentration of 10 mM in 100% DMSO, serially diluted in media, and added to HAEC
cells in media. 24 hours later, adeno-associated virus was added, followed by luciferase
assay after another 24 hours.

3.5. Discussion
Over two thousand compounds were tested for enhancement of adeno-associated viral
transduction, and 20 (0.9%) were identified as hits with enhancement of two-fold or
greater. These compounds represented many different types of pharmacologically active
agents. Although a variety of families of compounds were tested, several classes of
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molecules stood out as being overrepresented in the list of primary screening hits,
including EGFR tyrosine kinase inhibitors, antioxidants, nucleoside analogs, and
alkylating agents.
EGFR tyrosine kinase inhibitors were not studied in detail, although the presence of
several Tyrphostin compounds in screening results did agree with previous data that these
compounds enhance AAV2 transduction.
Several primary screening hits have antioxidant activity, including the top enhancer,
ellagic acid. However, dose-response studies with other compounds including caffeic
acid phenethyl ester, ascorbic acid, and N-acetyl cysteine, failed to show a smilar level of
benefit. A detailed investigation of ellagic acid effects on the cell-virus interaction found
that while viral DNA levels were unchanged, mRNA levels and reporter gene expression
levels were very high. However, levels of cellular mRNA and total protein also appeared
to increase.
1,10-phenanthroline, the second highest hit in primary screening, demonstrated
enhancement of viral transduction that was not replicated with a second metal chelator
tested, EDTA.

This compound was the only chemical tested which resulted in an

increase in viral DNA as measured by quantitative real time PCR, indicating that its
mechanism is unique amongst the compounds investigated. However, as multiple viral
pseudotypes which bind to different cell surface receptors all were enhanced by the
addition of 1,10-phenanthroline, the mechanism is not related to increased binding of the
virus to the cell surface.
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DNA damaging agents including nucleoside analogs and alkylating agents facilitated
AAV2 transduction, and specifically led to an increase in mRNA levels.

This is

consistent with previous research indicating that damaging cellular DNA enhances AAV
transduction. .18, 79, 80
Cell cycle arrestors may be beneficial for adeno-associated viral transduction, but the one
compound tested that was not identified in primary screening (NU 2058) did not enhance
transduction.
The results from this study demonstrated the feasibility of the high throughput screening
approach to identifying small molecule enhancers of AAV2. Furthermore, a small set of
strong enhancers of AAV2 has been identified and some mechanistic insight was gained.
These enhancers and their respective mechanisms can serve as a basis for further study.
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Chapter 4

4. Conclusions and Future Work
4.1. Conclusions
Gene therapy holds the potential to allow a new set of diseases to be prevented, treated,
or cured. Following successful delivery and expression of the target gene, cells produce
the therapy themselves, allowing targeted, novel treatments that were impossible in the
past.
While gene therapy holds such promise, there is a lot of research required to make this
dream a reality. A major challenge for all gene therapy treatments is to identify a vector
that will be safe and effective.
In many ways, adeno-associated virus is an ideal vector for gene delivery. This vector is
safe, causing no known human disease and evoking little to no immune response. The
ability to select from a variety of natural serotypes and/or engineer new serotypes allows
it to be targeted to specific organs and disease types. The most pressing drawback to the
use of this virus is limited efficacy.
In an effort to address this issue, we have used high throughput screening to identify
enhancers of AAV2 transduction of human endothelium. In the first screen, we used
siRNA knockdown of 5,520 human gene targets to identify siRNA enhancers. In the
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second screen, we treated HAEC with 2,320 chemical compounds to identify small
molecule enhancers.
The siRNA high throughput screen identified 10 siRNA sequence hits. One of the top
hits, the CLIC2(C) siRNA sequence, enhanced transduction due to an off-target effect
unrelated to a decrease in CLIC2 mRNA. The action of this siRNA was found to be
related to a hexamer seed region [5’-U2GUUUC7-3’] which was shared with several other
top siRNA sequence hits.
Although the specific mechanism by which the CLIC2(C) sequence acts remains
unknown, transcription profiling implicated the interferon pathway. Knockdown of the
interferon (alpha, beta, omega) receptor 2 was additionally shown to benefit transduction,
and addition of interferon alpha or beta was shown to hamper transduction. These results
have potential implications for cancer gene therapy, as one clinical strategy being studied
uses AAV2 to deliver interferon-β to cancer cells. Although these studies have shown
positive results, there is a possibility that repeat administration of the vector could be
inhibited by the interferon transgene.
The chemical compound screen identified individual chemical hits as well as several
categories of enhancing compounds.

Specifically, ellagic acid, 1,10-phenanthroline,

alkylating agents, nucleoside analogs, and EGFR protein tyrosine kinase inhibitors stood
out. Although antioxidants initially appeared to benefit viral transduction, additional
compounds which were tested such as ascorbic acid, n-acetyl cysteine, and curcumin all
failed to demonstrate a gene delivery benefit. Additional chemical functions such as cell
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cycle arrest and metal chelation did not appear to have strong enhancement effects.
EGFR protein tyrosine kinase inhibitors were not examined in great detail since their
mechanism of enhancing AAV has already been explored by other researchers.70
In primary screening, ellagic acid provided the strongest enhancement to AAV2
transduction, with nearly 8-fold stronger luminescence signal than control. Within the
dose range studied, ellagic acid showed a dose-dependent increase in transduction
efficiency with increasing dose. Detailed studies showed that the ellagic acid benefit can
be measured beginning with strongly increased mRNA levels, although viral DNA levels
are unchanged. However, there is some evidence that this may be due to a global
mechanism of increased mRNA transcription, and must be studied further to determine
whether this increase is specific to the AAV2 vector.
1,10-phenanthroline was the second-strongest hit identified in primary screening, with
over 6-fold enhancement of signal.

This enhancement comes downstream of viral

attachment to cell surface receptors, but increased viral DNA signal is observed. This
suggests that the effect of 1,10-phenanthroline comes at either the endosomal
processing/transport stage or the viral second-strand DNA synthesis stage of the viral
transduction process.

Given the metalloprotease inhibitor characteristics of this

compound, one possibility is that it protects the virus from degradation by
metalloproteases during endosomal processing.
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Both alkylating agents and nucleoside analogs were successful in enhancing AAV2
transduction. Both of these categories of chemicals damage DNA, and the cellular DNA
repair mechanisms may be implicated in assisting viral transduction.18, 79, 80

4.2. Future Work
4.2.1. siRNA Mechanism
Future work is needed to determine the significance of the hexamer seed region identified
in siRNA screening. A variety of different techniques can be used in an effort to tackle
this problem.
First, as the field of miRNA research develops and more information is added to
bioinformatic databases, the importance of this specific hexamer sequence may become
clearer. Specifically, monitoring of the microRNA databse at www.mirdb.org would be
beneficial.83, 84
Further transcriptional profiling with more controls added would allow finer tuning of
microarray results. Specifically, a comparison could include active CLIC sequence A or
B, active CLIC2 sequence C, and a mutated sequence with the mutation outside the
hexamer seed region. Transcripts which are similar for the active CLIC2 sequence but
not the mutant are then known to be related to CLIC2 knockdown rather than to the
hexamer seed region. Transcripts which are similar for the two sequences containing the
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hexamer seed region but that are lacking in CLIC2 sequence A or B would be the most
critical to investigate.
Additionally, mechanistic studies similar to what was performed for the chemical
compounds, including quantification of viral RNA and DNA, could be carried out for top
siRNA hits in order to provide a better understanding of where the siRNA enhances the
viral transduction pathway.

4.2.2. Examination of Additional Compound Hits
For this work, we selected a subset of screening hits to focus on. Of the screening hits,
there remain several compounds which were not prioritized in this work, but which could
yield

interesting

results.

Specifically,

SB

202190

(4-(4-Fluorophenyl)-2-(4-

hydroxyphenyl)-5-(4-pyridyl)-1H-imidazole) and DAPH (4,5-Dianilinophthalimide) are
ripe candidates for investigation. SB 202190 is a p38 MAP kinase inhibitor and had 3.5
fold enhancement in primary screening, which was the fourth highest hit. DAPH is a
protein tyrosine kinase inhibitor and had three-fold enhancement in primary screening,
making it the fifth highest hit. The p38 MAP kinase inhibition mechanism may prevent
the cell from producing immune-related cell signals.

The protein tyrosine kinase

inhibition of DAPH may or may not affect adeno-associated virus via the same
mechanism as the EGFR protein tyrosine kinase inhibition of the Tyrphostin compounds.
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4.2.3. Detailed Mechanism for Chemical Enhancement
Although the DNA damaging agents and EGFR protein tyrosine kinase inhibitors have
been previously investigated by other researchers, we have also identified a few
chemicals whose enhancement is via an unknown function. A closer examination of
these mechanisms may lead to a better understanding of AAV2 biology, ultimately
resulting in optimized formulations for viral delivery vectors or improved engineering of
the vector itself.
Although antioxidant effects were initially suspected to be the cause of ellagic acid
enhancement, these results were not confirmed by studies involving other antioxidants.
Ellagic acid appears to enhance viral transduction at a stage prior to or beginning with
transcription of mRNA. Also, ellagic acid increases mRNA transcription and protein
production non-specifically, although the extent to which viral mRNA and protein
production took place appears to be much higher than the level of increase that we have
measured. Initial studies can examine cellular mRNA and protein production to quantify
how much of the ellagic acid benefit is due to non-specific mechanisms. Additional
potential mechanisms for the enhancement of ellagic acid may be related to effects on the
cell cycle or activation of DNA repair mechanisms in response to DNA intercalation.
1,10-phenanthroline also enhanced AAV2 transduction via an unknown mechanism,
although in this case levels of viral DNA were increased as well as transgene mRNA and
protein levels. In order to study this in more depth, it will be useful to determine whether
the increase in DNA is due to an increased ability of the virus to survive the endosome
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and enter the nucleus, or if it is due to an increase in the second strand synthesis of DNA.
Known lyosome inhibitors could be added to the cells in order to determine if an increase
in viral transduction is possible as a result of decreased viral degradation in the
endosome. If so, then a combination of 1,10-phenanthroline and the lyosome inhibitor
could be added to cells. The combination of the two chemicals would be expected to
result in little to no additive effect. In order to determine if the increase is related to
second strand synthesis of DNA, a DNA synthesis inhibitor with and without the 1,10phenanthroline could be added to cells in order to block the second strand synthesis of
DNA. Then viral DNA quantities could be measured. If the viral DNA is the same in
both cases, then enhancement is likely due to an increase in DNA synthesis. If the viral
DNA quantity is different between the two, then enhancement occurs prior to DNA
synthesis.

4.2.4. Screening of Additional Compound Libraries
This study identified several chemical enhancers of adeno-associated virus transduction
out of a total of 2,320 compounds studied. However, much larger chemical libraries are
available for screening. A much larger data set of chemical enhancers could be generated
using these libraries, in order to identify a more complete understanding of adenoassociated virus biology and methods of enhancement.
Additionally, the primary screen presented here looked at chemicals at a single
concentration (10 µM in 0.1% DMSO). A more complete set of chemical enhancers
could be generated by examining more than one concentration, as the selected
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concentration could be toxic for some compounds or not high enough to be effective for
others.
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5. Appendix
Table A1. Presence of hexamer seed region within the 3’-untranslated region.
Gene Symbol
IFIT5
IFI44L
MX1
TRIM48
SLC5A2
CLIC2
OR51E1
LCK
SLC7A2
ABCA8
DRD1
ZMYND8
KALRN
GPR77
MLL
PIP5K1A
TAS2R13
ALPI
BACE1
TAS2R10
CAMKK1
C8G
ITPKA
GDPD1
RYR3
FLAD1
PDE5A
RAD50
VIPR2
GRPR
LPHN2
NCOA6
FZD2
HGS
GART
PIK3C2A

5'-GAAACA-3'
no match
hexamer in three locations within 3' UTR
no match
no match
no match
hexamer in three locations within 3' UTR
no match
no match
hexamer in one location within 3' UTR
no match
hexamer in one location within 3' UTR
hexamer in two locations within 3'UTR
no match
no match
hexamer in one location within 3' UTR
no match
no match
no match
no match
not found in database
no match
no match
no match
hexamer in two locations within 3' UTR
no match
no match
hexamer in one location within 3' UTR
hexamer in one location within 3' UTR
no match
no match
no match
no match
no match
no match
no match
hexamer in one location within 3' UTR
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Gene Symbol
CDK16
GPR126
FMNL1
DUSP4
PTPRD
GIT2
NR4A3
ADRBK2
SENP6
DGKD
NCOA1
ADRA2B
CNKSR1
CDK18
TPSAB1
USP10
KCNH5
KREMEN2

5'-GAAACA-3'
no match
hexamer in one location within 3' UTR
no match
hexamer in two locations within 3' UTR
no match
hexamer in three locations within 3' UTR
hexamer in two locations within 3' UTR
hexamer in one location within 3' UTR
hexamer in two locations within 3' UTR
hexamer in two locations within 3' UTR
hexamer in five locations within 3' UTR
hexamer in three locations within 3' UTR
no match
hexamer in one location within 3' UTR
no match
no match
hexamer in one location within 3' UTR
hexamer in one location within 3' UTR
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Table A2. HAEC mRNA transcripts that were up-regulated or down-regulated following delivery of CLIC(C)
siRNA relative to CLIC(C)-U4A mutant.
Transcript
ID

Gene
Symbol

8165692
7902541
8068713

IFI44L
MX1

7964640
7951091
7959482
8127987
7969091
8140907
7952339
7951341
7911331
7924463
7927089
7945347
7998115
8031997
8102530
8137668
7939912
8073332
8173627

SNORD50A

SNORD14C

TRIM48

Name

--interferon-induced protein 44-like
myxovirus
(influenza
virus)
resistance 1, interferon-inducible
------small nucleolar RNA, C/D box
50A
----small nucleolar RNA, C/D box
14C
------------------tripartite motif-containing 48
-----

RefSeq

p-value

SAM qvalue
(%)

Fold Change
(Negative Indicates
CLIC2 down-regulated
vs mutant)

--NM_006820
NM_002462

0.031631
0.022691
0.015001

17.9637
17.9637
17.9637

-2.73748
-2.00103
-1.86237

------NR_002743

0.017268
0.009011
0.019299
0.015405

17.9637
17.9637
17.9637
17.9637

-1.62343
-1.61372
-1.57954
-1.56698

----NR_001453

0.00999
0.020332
0.018541

17.9637
17.9637
17.9637

-1.55793
-1.53483
-1.50519

------------------NM_024114
-----

0.014682
0.014317
0.014317
0.014317
0.014317
0.014317
0.014317
0.014317
0.014317
0.005948
0.010579
0.002809

17.9637
17.9637
17.9637
17.9637
17.9637
17.9637
17.9637
17.9637
17.9637
17.9637
17.9637
17.9637

-1.43389
-1.40324
-1.40324
-1.40324
-1.40324
-1.40324
-1.40324
-1.40324
-1.40324
-1.4031
-1.40015
-1.3619
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Transcript
ID

8081233
7982751
8173156
8069508
8055486
8168412
8165656
8065853
8022761
7929072
7900214
8081107
7928821
8084605
7896746
8092594
8072139
7942379
7950003
7992756
7934731
7976806
8131705
7913801
7959144
7941863

Gene
Symbol

CCDC29
LOC554203

IFIT5

MRGPRD
C1D
RPL23P8

Name

RefSeq

------------coiled-coil domain containing 29
ENST00000333394
----alanyl-tRNA synthetase domain
BC029480
containing 1 pseudogene
------------interferon-induced protein with
NM_012420
tetratricopeptide repeats
--------------------------------MAS-related GPR, member D
NM_198923
----C1D nuclear receptor co-repressor
NM_006333
----ribosomal protein L23 pseudogene
NR_026673
8
-------------

p-value

SAM qvalue
(%)

Fold Change
(Negative Indicates
CLIC2 down-regulated
vs mutant)

0.004376
0.011742
0.012164
0.004879
0.008705
0.011567

17.9637
17.9637
17.9637
17.9637
17.9637
17.9637

-1.36033
-1.35719
-1.35029
-1.34807
-1.3451
-1.33906

0.001565
0.007025
0.010789
0.012384

17.9637
17.9637
17.9637
17.9637

-1.33826
-1.33543
-1.31968
-1.31614

0.000955
0.008624
0.010724
0.005136
0.010914
0.011726
0.004583
0.006148
0.023057
0.007131
0.020163
0.014037
0.004311

17.9637
17.9637
17.9637
17.9637
17.9637
20.4893
17.9637
17.9637
24.8533
19.0368
24.8533
22.0738
18.6434

-1.3111
-1.31104
-1.28762
-1.28731
-1.28075
-1.27162
-1.26927
-1.25061
1.25216
1.25487
1.25554
1.25831
1.25898

0.003384
0.015752
0.003355

18.6434
22.0738
18.6434

1.25992
1.27117
1.27129
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Transcript
ID

8122277
8137131
8060080
8120059
7925031
7932964
8175098
8150034
7972977
8124510
8019804

Gene
Symbol

OR6B2

FLJ30430
C1D
GPR119

HIST1H2BL
ROCK1

7980906
8052698
7921358
8026339

SNRPG

8164006
8062490

SNORA60

8115679
8129309
7914216

C1D

SNORA16A

Name

----olfactory receptor, family 6,
subfamily B, member 2
--hypothetical protein FLJ30430
C1D nuclear receptor co-repressor
G protein-coupled receptor 119
----histone cluster 1, H2bl
Rho-associated,
coiled-coil
containing protein kinase 1
--C1D nuclear receptor co-repressor
--small nuclear ribonucleoprotein
polypeptide G
--small nucleolar RNA, H/ACA box
60
----small nucleolar RNA, H/ACA box
16A

RefSeq

p-value

SAM qvalue
(%)

Fold Change
(Negative Indicates
CLIC2 down-regulated
vs mutant)

----NM_001005853

0.007724
0.009623
0.028654

19.0368
20.4893
24.8533

1.27417
1.27739
1.28917

--AK054992
NM_006333
NM_178471
----NM_003519
BC041849

0.01944
0.000801
0.006937
0.000619
0.007808
0.018187
0.035442
0.027604

22.8629
17.9637
18.6434
17.9637
18.6434
22.0738
24.8533
24.8533

1.29556
1.29809
1.302
1.30264
1.30586
1.32413
1.34068
1.34177

--NM_006333
--NM_003096

0.01478
0.005958
0.003357
0.016268

20.4893
18.6434
17.9637
20.4893

1.34784
1.34983
1.3693
1.42612

--NR_002986

0.041601
0.00077

24.8533
17.9637

1.46167
1.46669

----NR_003035

0.045774
0.010283
0.018496

24.8533
17.9637
18.6434

1.59728
1.70123
1.72586
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Table A3. Chemicals purchased from Sigma for screening hit confirmation and follow-up experiments.
Catalog Number

Compound Description

E2250
320056
S7067
D3943
B5002
T3434
T4693
T5193
C2538
C8221
A5762
W104
A2169
D7802
S0693
M2011
C1386
A8199
C1768
T7165
22040
N4286

Ellagic Acid
1,10-Phenanthroline monohydrate
SB 202190
DAPH
5-Bromo-2′-deoxyuridine
Tyrphostin AG 490
Tyrphostin AG 537
Tyrphostin AG 698
Carboplatin
Caffeic acid phenethyl ester
Adenine 9-β-D-arabinofuranoside
WIN 62,577
3′-Azido-3′-deoxythymidine
Daidzein
SB 204741
Melphalan
Curcumin
N-Acetyl-L-cysteine
Cytosine β-D-arabinofuranoside
Tyrphostin 23
β-Carotene purum
NU20580
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Table A4. Compound screening enhancer hits.
Compound Name
Ellagic acid
1,10-Phenanthroline monohydrate
Tyrphostin AG 698
4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4pyridyl)-1H-imidazole
4,5-Dianilinophthalimide
5-Bromo-2 -deoxyuridine
Tyrphostin AG 490
Carboplatin
Caffeic acid phenethyl ester
Vidarabine
WIN 62,577
7,4 -Dihydroxyflavone
3-Azido-3-deoxythymidine (AZT)
Daidzein
Resveratrol
N-(1-Methyl-1H-5-indolyl)-N′-(3-methyl-5isothiazolyl)urea

Function

Normalized
Luminescence

Antioxidant, pp60src tyrosine kinase
inhibitor
Metalloprotease inhibitor, metal chelator
EGFR protein tyrosine kinase inhibitor
p38 MAP kinase inhibitor

7.9

Protein tyrosine kinase inhibitor
Nucleoside analog, mutagen
JAK-2 protein tyrosine kinase inhibitor,
EGFR protein tyrosine kinase inhibitor
Alkylating agent, platinum analog
Antioxidant
Nucleoside analog, inhibits viral
replication
Tachykinin receptor NK1 antagonist
Antioxidant
Nucleoside analog,
reverse transcriptase inhibitor
Antioxidant, isoflavone
Antioxidant, flavanoid
Serotonin receptor 5-HT2B antagonist

3.0
2.6
2.5

6.4
3.7
3.5

2.5
2.5
2.4
2.4
2.3
2.2
2.2
2.1
2.1
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Compound Name
7,2 -Dihydroxyflavone
Melphalan
Tyrphostin AG 537
8-Bromo-cAMP sodium

Function

Normalized
Luminescence

Antioxidant, flavanoid
Alkylating agent
EGFR protein tyrosine kinase inhibitor
Protein kinase A activator

2.1
2.1
2.1
2.0
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